All In Biotech

Drug Trial Radar · NCT06472908

Efficacy and Safety of Colchicine After PCI

Efficacy and Safety of Colchicine After Percutaneous Coronary Intervention

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 8,862 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

8,862

Planned (sponsor's estimate)

Start

Jul 9, 2024

Primary completion

Jun 30, 2027

Study completion Aug 31, 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jun 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Colchicine (0.5 mg/day) was recommended by the U.S. Food and Drug Administration in 2023 for the anti-inflammatory treatment of coronary heart disease (CHD). However, colchicine is still not approved for CHD treatment in China. There is no large-scale clinical evidence that colchicine can be used to treat Chinese patients with CHD. Considering the low body weight of the East Asian population, it is unclear whether the recommended standard dose (0.5 mg/day) is suitable for Chinese patients. Therefore, we need to further explore the effects of different doses of colchicine on the efficacy and safety of clinical endpoints in the Chinese population with CHD. This study is a multicenter, prospective, randomized, controlled, double-blind, event-driven clinical study conducted in China. The primary objective of this study is to determine whether long-term treatment with different doses of colchicine reduces the incidence of cardiovascular events in Chinese patients undergoing PCI. The secondary objective is to determine the safety of long-term treatment with different doses of colchicine in this patient population.

Conditions

  • Coronary Heart Disease
  • Percutaneous Coronary Intervention
  • Colchicine

Interventions

  • Colchicine 0.5 mgDrug

    Colchicine 0.5 mg, one pill a day, oral intake

  • Colchicine 0.375 mgDrug

    Colchicine 0.375 mg, one pill a day, oral intake

  • PlaceboDrug

    Placebo, one pill a day, oral intake

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and ischemia-driven revascularizationTime frame: An estimated 2-4 years period

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The Second Hospital & Clinical Medical School, Lanzhou University

    Lanzhou, Gansu, China

  • The First Affiliated Hospital of Harbin Medical University

    Harbin, Harbin, China

  • Fuwai Huazhong Cardiovascular Hospital

    Zhengzhou, Henan, China

  • The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture

    Enshi, Hubei, China

  • Huangshi Central Hospital

    Huangshi, Hubei, China

  • Jingzhou Central Hospital

    Jingzhou, Hubei, China

  • Dongfeng General Hospital, Hubei University of Medicine

    Shiyan, Hubei, China

  • Shiyan Renmin Hospital

    Shiyan, Hubei, China

  • Taihe hospital

    Shiyan, Hubei, China

  • Suizhou Central Hospital

    Suizhou, Hubei, China

  • Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • China Resources and WISCO General Hospital

    Wuhan, Hubei, China

  • Fifth Hospital in Wuhan

    Wuhan, Hubei, China

  • Wuhan Asia Heart Hospital

    Wuhan, Hubei, China

  • Wuhan Central Hospital

    Wuhan, Hubei, China

  • Wuhan First Hospital

    Wuhan, Hubei, China

  • Wuhan Fourth Hospital

    Wuhan, Hubei, China

  • Wuhan Puren Hospital

    Wuhan, Hubei, China

  • Wuhan Sixth Hospital, Affiliated Hospital of Jianghan University

    Wuhan, Hubei, China

  • Wuhan Third Hospital

    Wuhan, Hubei, China

  • Wuhan Wuchang Hospital

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • Xiangyang First People's Hospital

    Xiangyang, Hubei, China

  • Xianning Central Hospital

    Xianning, Hubei, China

  • Yichang Central People's Hospital

    Yichang, Hubei, China

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • The General Hospital of Northern Theater Command of the Chinese People's Liberation Army

    Shenyang, Liaoning, China

  • Shandong Provincial Hospital

    Jinan, Shandong, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

  • Songjiang Hospital Affiliated with Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Shanxi Cardiovascular Disease Hospital

    Taiyuan, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.